Lupin enters China market with approval for influenza treatment Oseltamivir

Lupin Ltd has received approval from China’s National Medical Products Administration (NMPA) for its Oseltamivir Phosphate Oral Suspension, marking the company’s first product entry into the Chinese pharmaceutical market.

The approval is being executed in partnership with Yabao Pharmaceuticals, a leading player in China’s paediatric medicine segment, and represents a significant milestone in Lupin’s global expansion strategy.

The approved product — Oseltamivir Phosphate Oral Suspension 6 mg/mL — is primarily used for the treatment and prevention of influenza A and B. The medicine can be used for treating flu in patients aged two weeks and older, while it is approved for preventive use in individuals aged one year and above.

The oral suspension format is particularly important in paediatric care, where liquid formulations are easier for children to consume compared to tablets or capsules. The approval therefore gives Lupin access to a large and strategically important paediatric healthcare market in China.

In its statement, Lupin said the product will now be launched and commercialised in China to improve access to affordable influenza treatment, especially for children.

The development is notable because China remains one of the world’s largest pharmaceutical markets, but also one of the more difficult markets for foreign drugmakers to enter due to regulatory and localisation requirements. For Lupin, the approval signals a broader attempt to deepen its international footprint beyond traditional US and Indian markets.

Fabricio Egros, President – Corporate Development at Lupin, said the approval reflects the company’s strategy of expanding access to high-quality and affordable therapies while strengthening its position in paediatric healthcare.

Partner company Yabao Pharmaceutical also highlighted that the approval reinforces collaboration between the two companies and could help expand future research and development efforts in paediatric and chronic disease therapies.

Lupin currently operates across more than 100 countries and has a strong presence in respiratory, cardiovascular, anti-diabetic and anti-infective therapies. The company maintains 15 manufacturing facilities and seven research centres globally.

Disclaimer: This article is based on company announcements and publicly available information. Investors are advised to consult certified financial advisors before making investment decisions.